Kenney Stephanie 4

What Happened

• Stephanie Kenney, Chief Corporate Affairs Officer of Atrium Therapeutics (RNA), received equity awards reported on Form 4 dated 2026-04-22 for transactions dated 2026-04-20. The filing shows (1) 30,000 restricted stock units (RSUs) granted at $0.00 and (2) a 60,000-share derivative award (option-like grant) granted at $0.00. These were awards (not open-market purchases or sales) and carry no cash purchase price at grant.

Key Details

• Transaction date: 2026-04-20; Form 4 filed: 2026-04-22 (timely, two days after the transaction).
• Grants: 30,000 RSUs (F1) and 60,000 derivative shares/option-type award (F2); reported price $0.00.
• Shares owned after transaction: not specified in the supplied summary of the filing.
• Vesting (from filing footnotes):
  • F1 (RSUs): 25% vests March 20, 2027, then the remaining RSUs vest in three substantially equal yearly installments thereafter, subject to continuous service.
  • F2 (derivative/option): 25% of the underlying shares vest March 20, 2027, then the remainder vests in 36 substantially equal monthly installments thereafter, subject to continuous service.
• Filing contains no indication of a 10b5-1 plan, cashless exercise, sale, gift, or tax-withholding disposition in the provided summary.

Context

• These are standard time‑based compensation awards to an executive — RSUs convert to shares upon vesting; the derivative award appears to be an option-like grant that vests over time. Because no shares were sold or bought on the open market, this filing documents compensation rather than a market trade and does not by itself indicate an immediate bullish or bearish signal.